Arrowhead posts Phase 1/2a results for inhaled ARO-MMP7 in IPF trial
Arrowhead Pharmaceuticals reported results from a completed study testing ARO-MMP7 inhalation solution in healthy volunteers and idiopathic pulmonary fibrosis patients.
Arrowhead Pharmaceuticals had one notable update this week involving its inhaled therapy for idiopathic pulmonary fibrosis.
- ARO-MMP7 Inhalation Solution, tested in a Phase 1/2a study in normal healthy volunteers and participants with idiopathic pulmonary fibrosis1, is now marked completed, with 105 participants enrolled1. The study began with healthy volunteers receiving single ascending doses of ARO-MMP7, then moved to multiple-dose administration after review of safety and pharmacodynamic data1. Primary completion was listed as September 5, 2025, and results were first posted August 5, 2026, about eleven months later. The primary outcome tracked the number of participants with treatment-emergent adverse events1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.